Special considerations for carvedilol use in heart failure

Clyde W. Yancy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Remarkable improvements in morbidity and mortality caused by heart failure have been realized because of a greater understanding of the pathobiologic mechanisms of left ventricular dysfunction and the subsequent application of neurohormonal antagonism to the heart failure milieu. The median survival of patients with chronic heart failure has greatly increased with the use of effective medical therapy that includes angiotensin-converting enzyme inhibitors and β-blockers, especially carvedilol. Still to be addressed is the issue of clinical trials that underrepresent special populations of patients who are affected with heart failure (eg, the elderly, women, and African Americans). Even though heart failure may be a somewhat different illness in etiology, epidemiology, or responsiveness to medical therapy for each of these groups, it is of utmost importance that patients affected by heart failure be treated with agents that have been shown to be of benefit in the major controlled clinical trials in heart failure.

Original languageEnglish (US)
Pages (from-to)64-68
Number of pages5
JournalAmerican Journal of Cardiology
Volume93
Issue number9 SUPPL. 1
DOIs
StatePublished - May 6 2004

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Special considerations for carvedilol use in heart failure'. Together they form a unique fingerprint.

Cite this